XOMA Royalty completes LAVA Therapeutics acquisition in push to strengthen bispecific antibody pipeline

XOMA Royalty Corporation (Nasdaq: XOMA, XOMAO, XOMAP) has officially closed its previously announced acquisition of LAVA Therapeutics N.V., completing a transaction that reinforces XOMA’s expansion into royalty-bearing oncology assets and early-stage bispecific antibody programs linked to large-cap pharmaceutical partners. The company stated that the closing followed a successful tender offer in which more than ninety percent of LAVA Therapeutics’ outstanding shares were submitted for purchase, enabling a streamlined corporate reorganization and full ownership transition. XOMA Royalty emphasized that this acquisition forms part of its “strength in numbers” strategy, a model that pools future economic rights from multiple partnered drug programs to generate diversified milestone and royalty revenue over time. The acquisition also positions XOMA Royalty to control a set of clinical and preclinical bispecific antibody candidates that originated from LAVA Therapeutics’ γδ T-cell engager platform, including oncology assets that have existing collaborations with Johnson & Johnson and Pfizer.

XOMA Royalty confirmed that LAVA shareholders received approximately $1.04 in cash per share and one contingent value right (CVR) for each share tendered. The company stated that the CVR structure entitles former LAVA shareholders to a significant portion of any future proceeds derived from partnered and unpartnered LAVA assets, specifically 75 percent of net proceeds associated with the Pfizer and Johnson & Johnson programs and 75 percent of proceeds from any future out-licensing of unpartnered candidates. Management explained that this structure was intended to balance immediate liquidity for LAVA shareholders with potential upside as XOMA pursues monetization of the bispecific antibody portfolio. With the transaction’s completion, XOMA Royalty is expected to delist LAVA Therapeutics from Nasdaq as the reorganization process finalizes.

How the LAVA Therapeutics acquisition shapes XOMA Royalty’s growing oncology-focused economic rights platform

The acquisition provides XOMA Royalty with an expanded set of future royalty and milestone streams tied to T-cell-engaging oncology therapies, reflecting the company’s pivot over the last several years toward building the biopharmaceutical sector’s largest diversified royalty aggregator model. Industry analysts have noted that LAVA Therapeutics’ γδ T-cell bispecific approach has attracted interest from major pharmaceutical companies due to its potential to activate anti-tumor immune responses without the safety concerns commonly associated with traditional T-cell engagers. By acquiring LAVA’s programs at an early stage, XOMA Royalty gains exposure to long-horizon oncology development cycles supported by the resources and clinical scale of Johnson & Johnson and Pfizer. Investors following the announcement observed that such partnerships often serve as a pipeline de-risking mechanism, since milestone and royalty economics depend on the development progress and commercialization strategies of larger pharmaceutical collaborators rather than solely on the cash position of a small biotechnology company.

XOMA Royalty signaled that the LAVA Therapeutics assets complement its growing portfolio of partnered programs across immunology, oncology, metabolic disorders, and rare diseases. The company has spent recent years acquiring royalty streams from distressed, under-capitalized, or strategically repositioning biotechnology firms—an approach industry observers have described as “consolidating stranded shareholder value.” Within this framework, the LAVA transaction continues XOMA’s practice of purchasing long-duration assets that may generate significant upside if successful, even if the underlying programs remain in early clinical phases. Several third-party market watchers commented that obtaining two bispecific antibody programs tied to top-tier oncology developers provides XOMA Royalty with exposure to potential breakthrough therapies without the operational risk of running clinical trials or managing regulatory submissions directly.

Why investor sentiment may shift as XOMA Royalty integrates LAVA’s assets into its long-horizon value model

Market reaction to the acquisition’s closure has been measured, with share price movements reflecting investor awareness that royalty-based business models often generate returns gradually rather than immediately following deal completion. While XOMA Royalty’s valuation metrics remain elevated relative to the broader biotechnology group—most recently trading at a price-to-earnings ratio significantly above sector averages—analysts have attributed this premium to the company’s revenue structure, which is tied to milestone conversions, back-ended royalties, and the possibility of asset monetization. The addition of LAVA Therapeutics’ partnered pipeline may reinforce this premium if investors view the Pfizer and Johnson & Johnson programs as having meaningful commercial potential.

The institutional sentiment surrounding XOMA Royalty has remained neutral to cautiously positive in recent weeks, with market commentators noting that the company’s risk profile differs from traditional clinical-stage biotechnology firms. Because XOMA does not directly fund expensive late-stage clinical trials, fluctuations in development timelines may have less direct financial impact. However, the principal risk lies in the long-dated nature of the revenue streams: milestones may take years to materialize, and royalty payments only occur if the partnered assets reach regulatory approval and commercial success. The LAVA assets, currently at early stages, fall squarely into this category. Analysts evaluating the transaction have suggested that while short-term share price catalysts are limited, the deal strengthens XOMA’s pipeline depth and future optionality.

From a stock-performance perspective, XOMA Royalty’s recent trading patterns have shown lower volatility than many biotechnology peers. Market data tracked through publicly available sources indicates that the company has maintained stable momentum even as the broader biotech sector has experienced fluctuations tied to interest-rate expectations and macroeconomic sentiment. Investors have described XOMA Royalty’s strategy as providing exposure to high-value therapeutic categories, including oncology and autoimmune disorders, without the dilutive capital-raising cycles commonly seen in small-cap pharmaceutical developers. The LAVA Therapeutics acquisition reinforces this perception by broadening XOMA’s royalty-eligible assets in oncology, a market where successful therapies can produce multi-year commercial revenue streams.

How the CVR structure and partner-linked development pathways influence potential future value creation

The contingent value right issued to former LAVA Therapeutics shareholders is a key feature of the transaction and an element that may shape long-term perceptions of the deal’s value. A CVR tied to net proceeds from asset sales or partnered milestones means that upside for former shareholders—and for XOMA Royalty itself—depends heavily on development progress achieved by Pfizer and Johnson & Johnson. Analysts have emphasized that while CVR structures are common in biotechnology acquisitions involving early-stage programs, the payout timelines depend on clinical results, regulatory decisions, and subsequent commercial strategies. XOMA Royalty disclosed that former shareholders may receive up to approximately $0.23 per CVR as a secondary benefit, contingent upon liability evaluations and potential asset monetizations.

The company explained that integrating LAVA Therapeutics’ research assets into its business model will involve a multistep process, including delisting the acquired entity, consolidating its financial structure, and evaluating opportunities for licensing or partnership expansions. The strategic focus remains on strengthening the aggregation of milestone-eligible programs, an approach that diversifies risk across dozens of therapeutic candidates. Industry observers have noted that royalty corporations benefit when large pharmaceutical companies maintain strong R&D pipelines, particularly in oncology, where drug candidates often involve multiple phases of milestone triggers. With Johnson & Johnson and Pfizer advancing the bispecific antibody programs originally licensed from LAVA Therapeutics, XOMA Royalty is positioned to participate financially in results without assuming scientific or operational responsibility.

The company has repeatedly emphasized that its revenue generation is non-linear, with significant inflows occurring when partnered programs achieve developmental or commercial milestones. As such, the addition of new assets expands the probability that one or more pipeline programs may advance to value-creating inflection points. While none of the newly acquired assets guarantee future returns, their alignment with top-tier oncology developers may improve the long-term risk-reward profile.

How the acquisition of LAVA Therapeutics positions XOMA Royalty within broader sector trends in biotech asset consolidation

The LAVA Therapeutics acquisition occurs within a period of restructuring across the biotechnology sector, as numerous small-cap companies face funding constraints and increasingly seek corporate buyers or partnership-driven exits. XOMA Royalty’s deal strategy echoes a wider industry move toward consolidating early-stage programs into organizations capable of extracting value through royalty-based monetization. As capital markets adjust to a higher-rate environment and investors continue to prioritize companies with non-dilutive revenue models, royalty aggregators have gained attention for their ability to generate long-term economic rights from assets that individual biotech companies may struggle to advance independently.

Market participants have suggested that XOMA Royalty’s approach may position the company as a rising consolidator within the royalty-acquisition space, particularly as more biotechnology firms evaluate strategic alternatives. With the acquisition of LAVA Therapeutics now completed, the company gains additional depth in immuno-oncology, enhancing its exposure to therapeutic categories that have historically produced commercially successful biologics. The transaction’s structure also reflects an emerging preference for CVR-linked payouts, which allow shareholders to capture upside while enabling acquirers to manage near-term cash expenditure. As XOMA Royalty integrates the LAVA assets, industry analysts expect the company to continue pursuing similar transactions that add royalty-eligible programs at discounted valuations.